Statin Plus Ezetimibe In ASCVD

High-Intensity Statins have been the treatment of choice for ASCVD. However, the recent non-inferiority RACING study evaluates the role of combination moderate-dose statin plus ezetimibe to high-dose statin in ASCVD. Host Geoff Wall breaks down another potential GameChanger in Pharmacotherapy.The GameChanger Combination moderate-dose statins plus ezetimibe may be non-inferior to high-dose statins – and have the benefit of better tolerability. Show Segments 00:00 – Introductions 01:55 – Long-Term Efficacy and Safety of Moderate Intensity Statins with Ezetimibe 02:55 – Statins and Ezetimibe in ASCVD  13:52 – The GameChanger 20:50 – Connecting to Practice  22:01 – Closing Remarks Host Geoff Wall, PharmD, BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health References and resources:Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trialRedeem your CPE or CME creditCPE (Pharmacist) CME (Physician) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a Membership Prescribers: Get a Membership Continuing Education Information:Learning Objectives:1. Discuss the RACING study results comparing moderate-dose statin plus ezetimibe to high-dose statins2. Describe the known ‘nocebo’ effect of muscle-related statin adverse effects. 0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-22-310-H01-PInitial release date: 09/05/22Expiration date: 09/05/2023Additional CPE & CME details can be found here Follow CEimpact on Social Media:LinkedInInstagram